skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Integrating epigenomics into pharmacogenomic studies

Perspectives

(4542) Views  (1162) Full article downloads

Authors: Wei Zhang, R Stephanie Huang, M Eileen Dolan

Published Date November 2008 Volume 2008:1 Pages 7 - 14
DOI: http://dx.doi.org/10.2147/PGPM.S4341

Wei Zhang, R Stephanie Huang, M Eileen Dolan

Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA

Abstract: The goal of personalized medicine is to recommend drug treatment based on an individual’s genetic makeup. Pharmacogenomic studies utilize two main approaches: candidate gene and whole-genome. Both approaches analyze genetic variants such as single nucleotide polymorphisms (SNPs) to identify associations with drug response. In addition to DNA sequence variations, nongenetic but heritable epigenetic systems have also been implicated in regulating gene expression that could influence drug response. The International HapMap Project lymphoblastoid cell lines (LCLs) have been used to study genetic determinants responsible for expression variation and drug response. Recent studies have demonstrated that common genetic variants, including both SNPs and copy number variants (CNVs) account for a substantial fraction of natural variation in gene expression. Given the critical role played by DNA methylationin gene regulation and the fact that DNA methylation is currently the most studied epigenetic system, we suggest that profiling the variation in DNA methylation in the HapMap samples will provide new insights into the regulation of gene expression as well as the mechanisms of individual drug response at a new level of complexity. Epigenomics will substantially add to our knowledge of how genetics explains gene expression and pharmacogenomics.

Keywords: epigenetics, DNA methylation, gene expression, pharmacogenomics, HapMap, drug response








Readers of this article also read:

The genetic overlap of attention deficit hyperactivity disorder and autistic spectrum disorder
Genomics and proteomics: Applications in autoimmune diseases
Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine
The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent
Pharmacogenomics in osteoporosis: Steps toward personalized medicine
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine
Gene polymorphisms in association with self-reported stroke in US adults
Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy
The role of genetics in pre-eclampsia and potential pharmacogenomic interventions
Clinical applications of schizophrenia genetics: genetic diagnosis, risk, and counseling in the molecular era